Sanofi experiencing shortage of two Pompe disease drugs

Ed’s tales discover prescription drug pricing, affordability and entry, as nicely points surrounding patents, litigation, and laws. He’s additionally the writer of the morning Pharmalittle publication and the afternoon Pharmalot publication.

Sanofi is experiencing shortages of two medicines used to deal with Pompe illness, and the issue emerged shortly after the Meals and Drug Administration warned the corporate over manufacturing points on the Irish facility the place the medicine are made.

In current days, the drugmaker has alerted affected person teams and physicians in each the U.S. and Europe that provides of Myozyme, an older commonplace of care, and Nexviazyme, a more moderen therapy, are dwindling resulting from what has been described as a bottleneck within the closing manufacturing section, in addition to high quality management points at its Waterford plant.

The positioning is chargeable for what is named batch launch, which refers back to the closing high quality assurance and regulatory course of the place a manufactured quantity of drugs is formally licensed, accredited, and cleared for distribution and use by sufferers. This step is meant to confirm the batch of drugs meets security and efficiency necessities.